JP2021521143A5 - - Google Patents
Info
- Publication number
- JP2021521143A5 JP2021521143A5 JP2020555310A JP2020555310A JP2021521143A5 JP 2021521143 A5 JP2021521143 A5 JP 2021521143A5 JP 2020555310 A JP2020555310 A JP 2020555310A JP 2020555310 A JP2020555310 A JP 2020555310A JP 2021521143 A5 JP2021521143 A5 JP 2021521143A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- cdr2
- cdr1
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655417P | 2018-04-10 | 2018-04-10 | |
| US62/655,417 | 2018-04-10 | ||
| PCT/EP2019/059171 WO2019197506A1 (en) | 2018-04-10 | 2019-04-10 | Axl-specific antibodies for cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521143A JP2021521143A (ja) | 2021-08-26 |
| JP2021521143A5 true JP2021521143A5 (enExample) | 2022-04-18 |
| JP7681401B2 JP7681401B2 (ja) | 2025-05-22 |
Family
ID=66182546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555310A Active JP7681401B2 (ja) | 2018-04-10 | 2019-04-10 | がん処置のためのａｘｌ特異的抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210070869A1 (enExample) |
| EP (1) | EP3774904A1 (enExample) |
| JP (1) | JP7681401B2 (enExample) |
| CN (1) | CN112218895A (enExample) |
| AU (1) | AU2019250443A1 (enExample) |
| CA (1) | CA3095986A1 (enExample) |
| EA (1) | EA202092448A1 (enExample) |
| IL (1) | IL277861A (enExample) |
| MA (1) | MA52657A (enExample) |
| WO (1) | WO2019197506A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019505520A (ja) | 2016-01-13 | 2019-02-28 | ゲンマブ エー／エス | 抗体およびその薬物コンジュゲートの製剤 |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| WO2021013746A1 (en) * | 2019-07-19 | 2021-01-28 | Genmab A/S | Axl antibody-drug conjugates for use in treating cancer |
| AU2021208433A1 (en) * | 2020-01-14 | 2022-07-14 | Uswm Ct, Llc | Method of treatment of cancer or tumour |
| US11807688B2 (en) * | 2020-02-28 | 2023-11-07 | Les Laboratoires Servier | Anti-AXL antibodies and compositions |
| EP4259200A1 (en) * | 2020-12-11 | 2023-10-18 | Boehringer Ingelheim International GmbH | Formulation for multi-purpose application |
| AU2021451307A1 (en) * | 2021-06-16 | 2024-02-01 | Shanghai Sinobay Biotechnology Co., Ltd. | Antibody targeting axl protein and antigen binding fragment thereof, preparation method therefor and use thereof |
| EP4359439A1 (en) | 2021-06-24 | 2024-05-01 | Yeda Research and Development Co. Ltd | Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor |
| IL289525B2 (en) * | 2021-12-30 | 2023-03-01 | B G Negev Technologies And Applications Ltd At Ben Gurion Univ | Conjugated antibodies for cancer treatment |
| KR20250151447A (ko) * | 2023-02-22 | 2025-10-21 | 레졸루트 사이언스, 인크. | 종양-관련 대식세포를 표적화하기 위한 조성물 및 방법 |
| WO2024178140A1 (en) * | 2023-02-22 | 2024-08-29 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
| WO2026132321A1 (en) | 2024-12-19 | 2026-06-25 | Institut National de la Santé et de la Recherche Médicale | Axl inhibitors for the treatment of mastocytosis |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| CN101918452A (zh) | 2007-11-15 | 2010-12-15 | 中外制药株式会社 | 与Anexelekto结合的单克隆抗体及其利用 |
| CN102459344A (zh) | 2009-05-15 | 2012-05-16 | 中外制药株式会社 | 抗axl抗体 |
| CN103080136B (zh) | 2010-06-18 | 2015-08-12 | 霍夫曼-拉罗奇有限公司 | 抗Axl抗体及使用方法 |
| AU2012273955A1 (en) | 2011-06-22 | 2014-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| WO2012175691A1 (en) | 2011-06-22 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| US20160106861A1 (en) | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
| GB201410825D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| DK3169706T3 (da) | 2014-07-11 | 2020-03-09 | Genmab As | Antistoffer, der binder axl |
| WO2016097370A2 (en) * | 2014-12-18 | 2016-06-23 | Bergen Teknologioverføring As | Anti-axl antagonistic antibodies |
| CA2991805A1 (en) * | 2015-07-10 | 2017-01-19 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
| ES2896079T3 (es) * | 2016-02-26 | 2022-02-23 | Ono Pharmaceutical Co | Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario |
| US20190233522A1 (en) | 2016-07-08 | 2019-08-01 | Genmab A/S | New dosage regimens for antibody drug conjugates based on anti-axl antibodies |
-
2019
- 2019-04-10 EP EP19717837.9A patent/EP3774904A1/en active Pending
- 2019-04-10 CA CA3095986A patent/CA3095986A1/en active Pending
- 2019-04-10 CN CN201980037687.7A patent/CN112218895A/zh active Pending
- 2019-04-10 WO PCT/EP2019/059171 patent/WO2019197506A1/en not_active Ceased
- 2019-04-10 MA MA052657A patent/MA52657A/fr unknown
- 2019-04-10 AU AU2019250443A patent/AU2019250443A1/en not_active Abandoned
- 2019-04-10 US US17/046,199 patent/US20210070869A1/en active Pending
- 2019-04-10 JP JP2020555310A patent/JP7681401B2/ja active Active
- 2019-04-10 EA EA202092448A patent/EA202092448A1/ru unknown
-
2020
- 2020-10-07 IL IL277861A patent/IL277861A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7550168B2 (ja) | 抗ＢＣＭＡ抗体及びγ－セクレターゼ阻害剤を使用した併用療法 | |
| JP7681401B2 (ja) | がん処置のためのａｘｌ特異的抗体 | |
| CN111587124A (zh) | Ror1抗体免疫缀合物 | |
| JP7607564B2 (ja) | Ｐｍｅｌ１７に対する抗体及びその結合体 | |
| KR102303874B1 (ko) | 항-folr1 면역접합체 투여 레지멘 | |
| BR112019015950A2 (pt) | conjugados de anticorpo anti-ccr7 e fármaco | |
| JP2018525354A5 (enExample) | ||
| HK1221153A1 (zh) | 抗体-药物缀合物 | |
| JP2017537893A (ja) | 抗ｃｓ１抗体および抗体薬結合体 | |
| BR112020010937A2 (pt) | anticorpos anti-liv1 humanizados para o tratamento de câncer de mama | |
| CA2858133A1 (en) | Uses of immunoconjugates targeting cd138 | |
| CA3101790A1 (en) | Anti-cd37 immunoconjugate dosing regimens | |
| WO2016180941A1 (en) | Liquid compositions for anti-cd19 antibody-drug conjugates | |
| CN112368020A (zh) | 抗pd-1抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法 | |
| JP2022541591A (ja) | がんの処置のためのヒト化抗ｌｉｖ１抗体 | |
| JP2026501556A (ja) | 抗体薬物複合体 | |
| CA2965362A1 (en) | Egfr antibody-based combination therapy | |
| JP2025519980A (ja) | Ｐｄ－１阻害剤またはｐｄ－ｌ１阻害剤およびクローディン１８．２を標的にする抗体－薬物コンジュゲートによるがん処置 | |
| US20230181756A1 (en) | Ccr7 antibody drug conjugates for treating cancer | |
| JP2023543026A (ja) | がんの処置のためのヒト化抗ｌｉｖ１抗体 | |
| AU2024298986C1 (en) | Pharmaceutical composition containing anti-nectin4 antibody-drug conjugate and anti-pd-1 antibody and use thereof | |
| WO2024208354A1 (en) | Antibody drug conjugates | |
| TW202506722A (zh) | 使用pd-1或pd-l1抑制劑及靶向密連蛋白(claudin) 18.2之抗體藥物結合物之癌症治療 | |
| HK40112252A (en) | Antibodies to pmel17 and conjugates thereof | |
| TW202527996A (zh) | 使用抗ｃｄ３０抗體－藥物結合物治療癌症之方法 |